Q1 Sales Surge 135%: Legend Biotech's CAR-T Therapy Carvykti on Track for $2 Billion in 2025

Apr 16, 2025 12:13 CST Updated 12:13

Legend Biotech

Tumor Cell Immunotherapy Developer

Johnson & Johnson

Medical Device R&D and Manufacturer

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point them out in the comments. This article is only an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved); it does not constitute any investment advice.

On April 15, Johnson & Johnson released its Q1 2025 financial report,Operating revenue of $21.893 billion, a year-on-year increase of 2.4%. Among them,R&D expenditure reached $3.23 billion,At the same time, the company made significant progress in its new product pipeline during the quarter, including Tremfya in Crohn's disease.Approval in aspects, overall survival data of Rybrevant/Laz Cluze in non-small cell lung cancer, data of Icotekinra in plaque psoriasis, and the initiation of clinical trials for the general surgical robotic system Ottava.

In terms of products,2025Q1 Innovative DrugSales revenue of $13.873 billion, increased by 2.3% year-on-year; Oncology drug sales of $5.678 billion, increased by 17.9% year-on-year; CD38 antibody Darzalex sales of $3.237 billion, increased by 20.3% year-on-year.

Notably, Johnson & Johnson has collaborated with Legend Biotech to developBCMA CAR-T Therapy Carvykti Q1 2025 Sales Reach $369 Million, a Year-on-Year Increase of 135%! AndAndCarvykti 2025Sales are expected to reach $2 billion.

Carvykti（Cilta-cel (generic name: ciltacabtagene autoleucel) is a CAR-T therapy targeting B-cell maturation antigen,For adult patients with relapsed or refractory multiple myeloma who have previously received treatment regimens including proteasome inhibitors, immunomodulatory agents, and anti-CD38 antibodies, and have experienced disease progression during or after their last treatment.

Carvykti was granted the first CAR-T clinical trial application approval by the China National Medical Products Administration in 2018. Subsequently, it conducted clinical trials in multiple countries and regions worldwide, receiving various designations and approvals. On February 28, 2022, its U.S. marketing application was approved by the U.S. Food and Drug Administration; in May of the same year, the European Commission granted it conditional marketing authorization.

In 2023,Carvykti Sales Reach $500 Million

Reference: Johnson & Johnson 2025 Q1 Earnings Report